The Cancer Drug That Wears a Disguise (and Just Blew Up Wall Street)

At the highest dose tested (10 mg/kg), the confirmed response rate hit 32%. At the next dose down (8.6 mg/kg), it was 20%. Those numbers might sound modest in a vacuum, but context is everything.

Late-line colorectal cancer is a therapeutic graveyard. Patients who've burned through three or more lines of treatment have vanishingly few options. Standard-of-care response rates in this setting are dismal. A 32% response rate in these patients, from a Phase 1 trial no less, is genuinely surprising.

The drug also showed disease control rates between 84% and 90% across the dose levels tested, and preliminary progression-free survival clocked in at about 7.1 months at the top dose. For patients running out of options, seven months of disease control is meaningful.

Clean Safety in a Dirty Neighborhood

Perhaps even more impressive than the efficacy: the safety profile was remarkably clean. No dose-limiting toxicities. No interstitial lung disease (a feared side effect of many ADCs). No liver toxicity, no pancreatitis. The main issue was Grade 3 diarrhea in about 10% of patients, which was manageable with treatment.

For a drug hitting a target as broadly expressed as EpCAM, that safety profile is the Probody platform doing exactly what it's supposed to do. The mask is working. The drug is staying quiet until it reaches the tumor, then flipping the switch.

Wall Street Got the Memo

The market reaction was swift and dramatic. Analysts piled on with upgrades. HC Wainwright raised its price target from $10 to $17, calling Varseta-M a "$750 million peak opportunity" in late-line mCRC. JPMorgan upgraded the stock to "overweight" with a $12 target. Barclays, Piper Sandler, and Guggenheim all issued bullish calls.

CytomX is now targeting FDA alignment on a registrational trial design by mid-2026, with additional Phase 1 data expected at upcoming medical meetings. Combination studies with bevacizumab (a standard colorectal cancer drug) are already underway.

The $1.6 Billion Goodbye

On the very same day the Varseta-M data dropped, CytomX disclosed that Astellas had decided to walk away from their six-year T-cell engager collaboration.

The partnership, struck in March 2020, gave Astellas access to CytomX's Probody platform for developing masked bispecific antibodies targeting solid tumors. Astellas paid $80 million upfront, with the deal structured to include up to $1.6 billion in milestone payments plus royalties. As recently as 2024, CytomX had nominated two bispecific candidates under the deal, triggering $10 million in combined milestones.

But Astellas chose not to advance the remaining preclinical programs, and the partnership will formally end in Q2 2026. The stated reasons? Not publicly disclosed. The timing is curious, though: walking away from a platform on the same day that platform's lead program just posted its best data ever.

It's worth noting that Astellas's decision was specific to the T-cell engager programs, not the ADC pipeline. Different modality, different bet. And CytomX isn't exactly short on dance partners; collaborations with Bristol Myers Squibb, Regeneron, and Moderna all remain active.

What Happens Next

CytomX enters this next chapter with $137.1 million in cash, giving it runway through Q2 2027. That's enough time to hit the FDA milestone, generate more clinical data, and potentially start a pivotal trial.

The company also has a second clinical asset, CX-801 (a masked interferon therapy for advanced melanoma), with initial clinical data expected by end of 2026. And it filed a $250 million shelf registration, giving it the ability to raise capital if the stock holds.

The big question now is whether the Varseta-M data can hold up in a larger, registrational trial. Phase 1 results are encouraging but early; response rates can shift as more patients are treated and followed longer. The colorectal cancer landscape is also evolving quickly, with new targeted therapies for specific mutations gaining ground.

But if the mask keeps working, and the responses keep confirming, CytomX might just have a breakthrough ADC for colorectal cancer. That's a market very few have cracked yet.

Sometimes the best strategy is knowing when to take off the disguise.

The €2.3 Billion Bet That Hearing Aids Are the Next Big Thing in MedTech

Amplifon just dropped €2.3 billion to buy the company that makes the hearing aids it sells, creating a vertically integrated giant in one of medtech's fastest-growing markets. The deal reshapes an entire industry, and the competition should be worried.